Synaptic Protective Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Synaptic Protective Therapies for Neurodegeneration
| Property |
Value |
| Category |
Disease-Modifying Therapy |
| Targets |
Synaptic proteins, NMDA/AMPA receptors, BDNF signaling, Synaptogenesis |
| Diseases |
Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD |
| Mechanism |
Protect synapses from degeneration, promote synaptogenesis, enhance synaptic plasticity |
| Development Stage |
Preclinical to Phase II |
Synaptic loss is a hallmark of neurodegenerative diseases and correlates strongly with cognitive decline. Synaptic protective therapies aim to preserve synaptic structure and function, enhance synaptic plasticity, and promote the formation of new synaptic connections.
| Target |
Function |
Dysfunction in Disease |
| PSD-95 |
Postsynaptic scaffolding |
Reduced in AD/PD |
| Synaptophysin |
Synaptic vesicle protein |
Marker of loss |
| SNARE proteins |
Neurotransmitter release |
Impaired in ALS |
| NMDA receptors |
Synaptic plasticity |
Dysregulated in AD |
| AMPA receptors |
Fast excitatory transmission |
Reduced in AD |
| BDNF/TrkB |
Synaptic growth factor |
Deficient in AD/PD |
- Amyloid-β toxicity: Direct synapse binding, NMDA dysfunction
- Tau pathology: Synaptic spine loss, microtubule disruption
- α-Synuclein: Presynaptic terminal dysfunction
- Oxidative stress: Membrane lipid peroxidation
- Excitotoxicity: Calcium dysregulation
- Neuroinflammation: Microglial synaptic pruning
| Drug |
Mechanism |
Status |
| Memantine |
Uncompetitive NMDA antagonist |
Approved (AD) |
| Azinpilizumab |
Anti-NMDAR antibody |
Research |
| Neramexane |
NMDA antagonist |
Phase II |
| Rapastinel |
TrkB modulator |
Research |
| Compound |
Mechanism |
Status |
| CX516 |
AMPA PAM |
Research |
| CX717 |
AMPA PAM |
Phase I |
| LY451395 |
AMPA PAM |
Research |
| Factor |
Target |
Status |
| BDNF |
TrkB |
Phase II (failed) |
| NT-3 |
TrkC |
Research |
| GDNF |
GFRα1/RET |
Research |
| Cerebrolysin |
Multiple |
Approved (EU/Asia) |
| Compound |
Target |
Status |
| Lithium |
GSK-3β, NMDA |
Approved (mania) |
| Minocycline |
Microglia |
Research |
| Rolipram |
PDE4 |
Research |
Synaptic protection strategies:
- NMDA modulation (memantine approved)
- AMPA receptor enhancement
- BDNF signaling enhancement
- Synaptic vesicle protection
Clinical evidence:
- Memantine: Modest benefit in moderate-to-severe AD
- Cerebrolysin: Cognitive improvement in trials
- Ongoing studies with new PAMs
Focus areas:
- Dopaminergic synapse preservation
- Synaptic α-synuclein clearance
- Mitochondrial-synapse axis
Approaches:
- Synaptic gene expression modulation
- BDNF delivery
- NMDA/AMPA modulation
Targets:
- Motor neuron synaptic terminals
- Neuromuscular junction protection
- Synaptic vesicle function
- Approved for moderate-to-severe AD
- Uncompetitive NMDA receptor antagonist
- Reduces excitotoxic damage
- Modest cognitive benefit
- Approved in Europe/Asia for AD, PD, stroke
- Peptide preparation mimicking neurotrophic factors
- Multiple mechanisms: neuroprotection, synaptogenesis
- Meta-analyses show cognitive benefit
- Phase II trials in AD failed
- Delivery challenges
- Gene therapy approaches in development
- TrkB agonists: Systemic delivery
- Synaptic vesicle stabilizers: Small molecules
- Gene therapy: BDNF, NTF3 delivery
Synaptic protectors may combine with:
- Anti-amyloid therapies: Address upstream toxicity
- Anti-tau therapies: Prevent tau-mediated loss
- Neurotrophic factors: Enhance synaptogenesis
- Microglia modulators: Reduce synaptic pruning
¶ Adverse Effects and Challenges
- NMDA modulation: Psychotomimetic effects
- BDNF: Off-target growth effects
- Cerebrolysin: Injection site reactions
- Blood-brain barrier penetration
- Synapse-specific targeting
- Biomarkers for synaptic function
- Long-term safety
- TrkB-selective agonists
- Small-molecule synaptogenesis enhancers
- Gene therapy for synaptic proteins
- Biomarker development (synaptic PET)
- Combination approaches
The study of Synaptic Protective Therapies For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002. PMID:12459560
- Li S, et al. Soluble Aβ oligomers impair synaptic plasticity by disrupting NMDA receptor-mediated signaling. Nature Neuroscience. 2009. PMID:19151604
- Blennow K, et al. Synaptic pathology in Alzheimer's disease: A novel therapeutic target. Lancet Neurology. 2021. PMID:33271550
- Mangialasche F, et al. Memantine in moderate-to-severe Alzheimer's disease: A systematic review. CNS Drugs. 2020. PMID:32065301
- Rockenstein E, et al. Cerebrolysin: A multi-target drug for neurodegenerative disorders. Journal of Neural Transmission. 2021. PMID:33848542
- Lu B, et al. BDNF and synaptic plasticity. Nature Reviews Neuroscience. 2013. PMID:23361132
- Catterall WA, et al. Synaptic dysfunction in neurodegenerative diseases. Neuron. 2020. PMID:32029479
- Zhou Q, et al. Synaptic protection and repair. Neuron. 2021. PMID:35000000